알레르겐 표준화
Allergen standardization
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Allergen immunotherapy (AIT) and diagnostic tests are based on well qualified allergen extracts, which are derived from biologic organisms. The allergenicity of the extracts is markedly affected by the climate, soil, year of production, storage methods, and manufacturing processes. Thus, standardization is a crucial process to guarantee the clinical efficacy and safety of the treatment and diagnostic reagents in allergic diseases. There are 2 different standardization processes, one is In vivo and the other is in vitro standardization. In vivo standardization is done by skin prick or intradermal tests. For in vitro standardization, measurements of weight/volume and protein nitrogen units have been widely used since the early period of AIT. In the 1970s, immunological methods such as radial immunodiffusion, enzyme-linked immunosorbent assay (ELISA) inhibition test and basophil activation test were developed. Allergen potency measured by ELISA inhibition test reflects the potency measured by skin tests and has been widely used for quality control of batch-to-batch variation. Recently, standardizations focused on the major allergen content of extracts have developed. Standardization for major allergens requires reliable reference materials (RMs) made of recombinant allergens and 2-site ELISA kits. However, only a few reliable RM and 2-site ELISA kits are available. For the standardization process, allergen RMs are essential. The Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration provides 19 allergen RMs, and our research team also proved 9 RMs which are important in Korea. In conclusion, allergen standardization is an essential process for the development of reliable treatment and diagnostic reagents, and allergy specialist should be familiar with the concept of allergen standardization.
Abstract
Allergen immunotherapy (AIT) and diagnostic tests are based on well qualified allergen extracts, which are derived from biologic organisms. The allergenicity of the extracts is markedly affected by the climate, soil, year of production, storage methods, and manufacturing processes. Thus, standardization is a crucial process to guarantee the clinical efficacy and safety of the treatment and diagnostic reagents in allergic diseases. There are 2 different standardization processes, one is In vivo and the other is in vitro standardization. In vivo standardization is done by skin prick or intradermal tests. For in vitro standardization, measurements of weight/volume and protein nitrogen units have been widely used since the early period of AIT. In the 1970s, immunological methods such as radial immunodiffusion, enzyme-linked immunosorbent assay (ELISA) inhibition test and basophil activation test were developed. Allergen potency measured by ELISA inhibition test reflects the potency measured by skin tests and has been widely used for quality control of batch-to-batch variation. Recently, standardizations focused on the major allergen content of extracts have developed. Standardization for major allergens requires reliable reference materials (RMs) made of recombinant allergens and 2-site ELISA kits. However, only a few reliable RM and 2-site ELISA kits are available. For the standardization process, allergen RMs are essential. The Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration provides 19 allergen RMs, and our research team also proved 9 RMs which are important in Korea. In conclusion, allergen standardization is an essential process for the development of reliable treatment and diagnostic reagents, and allergy specialist should be familiar with the concept of allergen standardization.
참고문헌 (36)
- Noon L, "Preophylaxctic inoculation against hay fever", Lancet, 177, pp.1572~1573 (1911)[DOI]
- Esch RE, "Allergen source materials and quality control of allergenic extracts", Methods, 13, pp.2~13 (1997)[DOI]
- Jutel M, "International consensus on allergy immunotherapy", J Allergy Clin Immunol, 136, pp.556~568 (2015)[DOI]
- Slater JE, "The US Food and Drug Administration review of the safety and effectiveness of nonstandardized allergen extracts", J Allergy Clin Immunol, 129, pp.1014~1019 (2012)[DOI]
- Slater JE, "Middleton's allergy: principle and practice", pp.2014, Elsevier
- Codina R, "Considerations about pollen used for the production of allergen extracts", J Allergy Clin Immunol Pract, 3, pp.676~682 (2015)[DOI]
- 정경용, "Standardization of Weed Pollen Extracts, Japanese Hop and Mugwort, in Korea", Yonsei Medical Journal, 57(2), pp.399~406 (2016), 연세대학교의과대학[DOI]
- Zimmer J, "Standardization and regulation of allergen products in the European Union", Curr Allergy Asthma Rep, 16, pp.21~ (2016)[DOI]
- 박중원, "Different Responses in Induction of Allergen Specific Immunoglobulin G4 and IgE-Blocking Factors for Three Mite Subcutaneous Immunotherapy Products", Yonsei Medical Journal, 57(6), pp.1427~1434 (2016), 연세대학교의과대학[DOI]
- Henmar H, "Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy", Clin Exp Immunol, 153, pp.316~323 (2008)[DOI]
- Reuter A, "New frontiers in allergen standardization", Clin Exp Allergy, 39, pp.307~309 (2009)[DOI]
- Dreborg S, "Precision of biological standardization of allergenic preparations", Allergy, 47(4 Pt 1):), pp.291~294 (1992)[DOI]
- Turkeltaub PC, "Biological standardization of allergenic extracts", Allergol Immunopathol (Madr), 17, pp.53~65 (1989)
- May JC, "Optimization of parameters in protein nitrogen unit precipitation procedure for allergenic extracts", J Allergy Clin Immunol, 63, pp.87~97 (1979)[DOI]
- Cooks RA, "The preparation and standardization of pollen extracts for the treatment of hay fever", J Allergy Clin Immunol, 4, pp.87~91 (1933)
- Vereda A, "Peanut allergy: clinical and immunologic differences among patients from 3 different geographic regions", J Allergy Clin Immunol, 127, pp.603~607 (2011)[DOI]
- Hoffmann HJ, "The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease", Allergy, 70, pp.1393~1405 (2015)[DOI]
- King TP, "Isolation and characterization of allergens from ragweed pollen. II", Biochemistry, 3, pp.458~468 (1964)[DOI]
- Cox L, "Allergen immunotherapy: a practice parameter second update", J Allergy Clin Immunl, 120(3 Suppl), pp.S25~S85 (2007)[DOI]
- Bousquet J, "Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper", J Allergy Clin Immunol, 102(4 Pt 1), pp.558~562 (1998)[DOI]
- Park JW, "Der p 2 isoallergens have different allergenicity, and quantification with 2-site ELISA using monoclonal antibodies is influenced by the isoallergens", Clin Exp Allergy, 32, pp.1042~1047 (2002)[DOI]
- Jeong KY, "Monoclonal antibodies to recombinant Der f 2 and development of a two-site ELISA sensitive to major Der f 2 isoallergen in Korea", Allergy, 57, pp.29~34 (2002)
- Grier TJ, "Major allergen measurements: sources of variability, validation, quality assurance, and utility for laboratories, manufacturers, and clinics", Allergy Asthma Proc, 23, pp.125~131 (2002)
- Fatima Ferreira, "Molecular Approach to Allergy Diagnosis and Therapy", Yonsei Medical Journal, 55(4), pp.839~852 (2014), 연세대학교의과대학[DOI]
- van Ree R, "The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification", Allergy, 63, pp.310~326 (2008)[DOI]
- Kaul S, "Standardization of allergen products: 3. Validation of candidate European Pharmacopoeia standard methods for quantification of major birch allergen Bet v 1", Allergy, 71, pp.1414~1424 (2016)[DOI]
- Spiric J, "Model for quality control of allergen products with mass spectrometry", J Proteome Res, 16, pp.3852~3862 (2017)[DOI]
- Carnes J, "Detection of allergen composition and in vivo immunogenicity of depigmented allergoids of Betula alba", Clin Exp Allergy, 39, pp.426~434 (2009)[DOI]
- Tscheppe A, "Recombinant allergens in structural biology, diagnosis, and immunotherapy", Int Arch Allergy Immunol, 172, pp.187~202 (2017)[DOI]
- Morrow KS, "Regulatory aspects of allergen vaccines in the US", Clin Rev Allergy Immunol, 21, pp.141~152 (2001)
- 정경용, "Standardization of House Dust Mite Extracts in Korea", Allergy, Asthma & Immunology Research, 4(6), pp.346~350 (2012), 대한천식알레르기학회
- 정경용, "Preparation and Characterization of an Extract of German Cockroach From a Korean Source", Allergy, Asthma & Immunology Research, 5(2), pp.102~105 (2013), 대한천식알레르기학회
- Jeong KY, "IgE reactivity of recombinant Pac c 3 from the Asian needle ant (Pachycondyla chinensis)", Int Arch Allergy Immunol, 169, pp.93~100 (2016)[DOI]
- 정경용, "Current Status of Standardization of Inhalant Allergen Extracts in Korea", Allergy, Asthma & Immunology Research, 6(3), pp.196~200 (2014), 대한천식알레르기학회
- Helm RM, "Production and testing of an international reference standard of short ragweed pollen extract", J Allergy Clin Immunol, 73, pp.790~800 (1984)[DOI]
- Ford A, "A collaborative study on the first international standard of Dermatophagoides pteronyssinus (house dust mite) extract", J Allergy Clin Immunol, 75, pp.676~686 (1985)[DOI]